language_icon
EN
HI

Biocon Share price

BIOCON

380.4

1.85 (-0.48%)
NSE
BSE
Last updated on 8 May, 2026 | 15:56 IST
Today's High

396.40

Today's Low

377.25

52 Week Low

317.00

52 Week High

424.95

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Biocon Chart

Biocon Share Key Metrics

Volume
56.80 L
Market Cap
61659.33 CR
LTQ@LTP
15@380.40
ATP
388.87
Var Margin
15.45 %
Circuit Range
344.05-420.45
Delivery %
48.11 %
Value
220.87 CR
ASM/GSM
No
Market Lot
1

Summary

Biocon share price stands at ₹380.4 at 8 May, 2026 | 15:56. The stock Biocon intraday movement has stayed between ₹377.25 and ₹396.40, while on a 52-week basis it has fluctuated from ₹317.00 to ₹424.95.
In terms of trading activity, Biocon has recorded a volume of 5679695 shares. The Biocon has a market cap of ₹1620907773. The stock’s Average Traded Price (ATP) stands at ₹38887, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 15, 38040.
The Biocon operates within a circuit range of ₹344.05-420.45 – ₹344.05-420.45, with a Value of ₹220.87 CR. The Delivery Percentage for the day is 48.11%. Additionally, Biocon currently falls under the No framework, and trades with a market lot size of 1.

Biocon Fundamentals

View More
P/E Ratio

102.64

P/B Ratio

1.64

Div. Yield

0.13

Sector P/E

68.14

Sector P/B

3.54

Sec. Div. Yield

0.56

Biocon Resistance and Support

Pivot 382.72

Resistance

First Resistance

385.84

Second Resistance

389.42

Third Resistance

392.54

Support

First Support

379.14

Second Support

376.02

Third Support

372.44

Biocon Futures & Options

380.4

-1.85 (-0.48%)

link_white_icon

Biocon Option Chain

View Price, OI, Greeks & More...
View All

26MAY26

380.25

-4.30 (1.12%)

30JUN26

383.20

-3.95 (1.02%)

28JUL26

384.80

-3.70 (0.95%)

BIOCON|26MAY26 CE 380.00

10.70

-3.1 (-22.46%)

BIOCON|26MAY26 PE 385.00

12.15

0.3 (2.53%)

Biocon Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

44.91%

Mutual Fund

16.53%

Insurance

6.16%

Foreign Institutional Investors

7.52%

Domestic Institutional Investors

1.38%

Retail

23.49%

Others

0.01%

Total Promoters
MAR '26
44.91%

Biocon Corporate Actions

DateAgenda
2026-05-07Audited Results & Final Dividend
2026-02-12Quarterly Results
2025-11-11Quarterly Results
2025-10-01Redemption (Part) of NCD
2025-08-07Quarterly Results
2025-05-08Audited Results & Final Dividend
2025-04-23Others
2025-04-04To consider Fund Raising
2025-01-30Quarterly Results & Others
2025-01-27Others

Biocon News

Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore

Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.
May 08 2026 10:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.
May 08 2026 00:05:00

Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities

Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Acquisition

Biocon plans to acquire the remaining ~2% equity stake in its material subsidiary, Biocon Biologics. The acquisition, valued at Rs. 330.73 crores through a preferential issue of Biocon shares, will increase its ownership to approximately 99.99%, aiming to fully integrate the biosimilars business.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Outcome Of Board Meeting_Completion Of Tenure Of Statutory Auditors

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate

Biocon's Board has appointed six new Directors, comprising five Independent Directors and one Non-Executive Non-Independent Director. These appointments are effective from August 01, 2026, and are subject to shareholder approval.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Change in Management

Biocon's board approved the appointment of six new directors, comprising five independent directors and one non-executive non-independent director. These appointments are effective August 1, 2026, and are subject to shareholder approval through postal ballot.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Fixation Of Record Date For Dividend

Biocon Limited has set July 3, 2026, as the record date for its final dividend. Eligible shareholders will receive ₹0.50 per equity share for FY26.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Corporate Action-Board approves Dividend

Biocon's Board recommended a final dividend of ₹0.50 per share for FY26, equivalent to 10% of the ₹5 face value. Payment is scheduled by August 31, 2026, subject to shareholder approval.
May 07 2026 23:05:00
Read More

About Biocon

NSE : 11373  
BSE : 532523  
ISIN : INE376G01013  

HISTORY AND CERTAIN CORPORATE MATTERSOur Company was incorporated as Biocon India Private Limited onNovember 29 1978 under the Companies Act. The word `Private' wasdeleted from our name under the provisions of Section 43A(2) of theCompanies Act with effect from July 1 1995. Thereafter our Company wasconverted to a private limited company under the provisions of Section43(2A) of the Companies Act with effect from December 21 2000. It wasreconverted into a public limited company on June 18 2001. The name ofour Company was changed from Biocon India Limited to Biocon Limited anda fresh certificate of incorporation consequent on change of name wasissued by the RoC on November 19 2003.Our Corporate StructureOur existing corporate structure is as under:Biocon LimitedClinigene International PrivateLimited (100.00%)Biocon Biopharmaceuticals PrivateLimited (51.00%)Syngene International PrivateLimited (99.99%)Interest of Promoters Directors and Key Managerial PersonnelExcept as stated in ?Related Party Transactions? on page 84 of this RedHerring Prospectus and to the extent of shareholding in our Companythe Promoters do not have any other interest in our business.Our Promoters have significant rights in our Company under the terms ofour Articles of Association. For additional information please referto the section entitled ?Main Provisions of Articles of Association ofBiocon Limited? on page 168 of this Red Herring Prospectus.Except to the extent of their compensation and to the extent of ESOPif any as mentioned on page 165 of this Red Herring Prospectus andtheir shareholding or shareholding of companies they represent theDirectors other than Promoter Directors do not have any otherinterest in our Company. Our Director Mr. John Shaw is the husband ofour Chairman & Managing Director Ms. Kiran Mazumdar-Shaw. OurDirector Prof. Ravi Mazumdar is the brother of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw. Our alternate Director Prof.Catherine Rosenberg is the sister-in-law of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw.The key managerial personnel of our Company do not have any interest inour Company other than to the extent of the remuneration or benefits towhich they are entitled to as per their terms of appointment andreimbursement of expenses incurred by them during the ordinary courseof business and to the extent of the Equity Shares held by them in theCompany if any and options granted to them under the ESOP.

Read More

Biocon Management

NamePosition
Kiran Mazumdar-ShawChairperson
Ravi Rasendra MazumdarNon Independent & Non Executive Director
View More

Biocon FAQs

The Buying Price of Biocon share is 380.4 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Biocon stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Biocon shares is 102.64. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Biocon shares is 1.64. Useful to assess the stock's value relative to its book value.

To assess Biocon’s valuation compare Sector P/E, P/B which are 68.14 & 3.54 with sector averages, along with growth rates and financial metrics.

The Market Cap of Biocon is 61659.33 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Biocon share price is 424.95 & 317.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Biocon belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost